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ABSTRACT 
Volatile anesthetics protect myocardium 
against reversible and irreversible ischemic injury. 
Experimental evidence from several in vitro and in 
vivo animal models demonstrates that volatile 
agents enhance the recovery of stunned 
myocardium and reduce the size of myocardial 
infarction after brief or prolonged coronary artery 
occlusion and reperfusion, respectively. This 
protective effect persists after the anesthetic has 
been discontinued, a phenomenon known as 
anesthetic-induced preconditioning (APC). Recent 
clinical data also demonstrates evidence of APC in 
patients during cardiac surgery. Thus, 
administration of volatile anesthetics may 
represent a novel therapeutic approach that 
reduces morbidity and mortality associated with 
perioperative myocardial ischemia and infarction. 
The mechanisms responsible for APC appear to 
be similar to those implicated in ischemic 
preconditioning , but nonetheless have subtle 
differences. Accumulating evidence indicates that 
APC is characterized by complex signal 
transduction pathways that may include adenosine 
receptors , G proteins, protein kinase C, reactive 
oxygen species, and sarcolemmal or mitochondrial 
-Address all correspondence to: Paul S. Pagel, Medical College of Wisconsin, 
MEB·M4280, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA 
c·mail: pspage1@mcw.edu 
KATP channels. Opioid analgesics may further 
enhance APC as well. This article will review 
recent advances in the understanding of 
mechanisms responsible for volatile anesthetic-
induced myocardial protection. 
INTRODUCTION 
A growing body of experimental and clinical 
evidence indicates that volatile anesthetics protect 
myocardium against ischemic injury. Delineating 
the mechanisms that mediate this beneficial anti-
ischemic effect has been a difficult task because 
volatile agents profoundly affect cardiovascular 
function. Volatile anesthetics cause dose-related 
depression of myocardial contractility, reduce 
arterial and coronary perfusion pressure, produce 
coronary vasodilation, affect electrophysiological 
function, and modify autonomic nervous system 
activity to varying degrees. The anti-ischemic 
effects of volatile anesthetics may be partially 
attributed to a favorable reduction in myocardial 
oxygen consumption, preservation of energy-
dependent cellular functions, and increases in 
coronary blood flow. Nevertheless, it is highly 
unlikely that alterations in myocarqial metabolism 
and coronary perfusion are solely responsible for 
myocardial protection duril)g administration of 
these drugs. Multiple endogenous signal 
transduction pathways, all o(which appear to act 
through the adenosine triphosphate-sensitive 
196 
potassium (KATP) channel as an integral 
component, have been implicated in mediating the 
salutarY' effects of volatile anesthetics. In this 
review, we will discuss recent developments in the 
understanding of mechanisms responsible for 
volatile anesthetic-induced myocardial protection. 
BACKGROUND 
Laboratory investigations performed over 
the past 15 years repeatedly demonstrated that 
volatile anesthetics attenuate reversible and 
irreversible damage associated with myocardial 
ischemia. Halothane was shown to reduce ST 
segment elevation during brief coronary artery 
occlusion in dogs [1], consistent with a decrease in 
acute ischemic injury. Halothane also preserved 
contractile function and ultrastructural integrity 
during cardioplegic arrest [2]. Enflurane 
decreased lactate production during coronary 
artery stenosis when perfusion pressure was 
maintained [3], and preservation of high-energy 
phosphate levels was coupled to these protective 
effects [4]. Isoflurane and desflurane enhanced 
left ventricular diastolic function during acute 
45 ~~ 
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coronary artery occlusion [5]. Halothane [6, 7, 8], 
enflurane [6,9, 10], isoflurane [6,7,9], and 
sevoflurane [11] were shown to improve the 
functional recovery of isolated hearts subjected to 
global ischemia and reperfusion. Halothane and 
isoflurane also enhanced the functional recovery 
of stunned myocardium in vivo [12, 13]. 
Halothane [14] and isoflurane [15] reduced 
myocardial infarct size in dogs, and this protective 
effect persisted despite discontinuation of the 
volatile agent before prolonged coronary artery 
occlusion [15]. This phenomenon (figure 1) was 
termed "anesthetic-induced preconditioning" 
(APC), and was characterized by a short-term 
memory phase similar to that of ischemic 
preconditioning (IPC). APC has also been 
described in rats [16] and rabbits [17] . 
Sevoflurane decreased the time threshold level of 
the ischemic stimulus required to protect against 
infarction during IPC [18]. These results 
suggested that volatile agents and brief ischemic 
episodes may produce synergistic protection 
against subsequent irreversible ischemic damage. 
Volatile anesthetics may also exert 
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Figure 1. Isoflurane preconditions myocardium by activation of KATP channels in 
dogs subjected to coronary artery occlusion and reperfusion. Isoflurane significantly 
(P < 0.05) reduced infarct size in the absence (I) and presence (I+PC) of ischemic 
preconditioning (PC). Isoflurahe produced profound reductions in myocardial infarct 
size, and this protective effect was associated with an acute memory period (I+M). 
Isoflurane-induced preconditioning was attenuated by the KATP channel antagonist 
glyburide (I+M+GLB). Other groups: control (CON), glyburide alone (GLB). (Adapted 
with permission of authors and publisher [15] .) 
Anesthetic-induced myocardial protection 
beneficial actions on coronary collateral perfusion 
to ischemic myocardium. Volatile anesthetics 
produce coronary vasodilation by activating KATP 
channels [11, 19, 20, 21, 22, 23] or by favorably 
affecting intracellular Ca2+ handling in vascular 
smooth muscle cells [24]. Halothane has been 
shown to attenuate reductions in coronary 
collateral perfusion associated with acute coronary 
occlusion [25]. Halothane also enhances the ratio 
of myocardial oxygen delivery to consumption in 
collateral-dependent myocardium [25]. 
Sevoflurane increases coronary collateral blood 
flow to ischemic myocardium when perfusion 
pressure is maintained at a constant level [23, 26]. 
Sevoflurane also improves functional recovery of 
coronary vascular reactivity and nitric oxide 
release in isolated hearts after global ischemia 
[11]. Halothane has been shown to reduce 
cyclical changes in coronary blood flow and 
prevent the development of platelet thrombi in the 
presence of a critical coronary artery stenosis [27]. 
Volatile anesthetics attenuate neutrophil and 
platelet aggregation [28] and also inhibit cytokine-
induced cell death [29] after ischemia-reperfusion 
injury in coronary vessels. 
The precise mechanisms responsible for 
anesthetic-induced myocardial protection against 
ischemia remain unclear despite extensive study. 
While it is clear that volatile anesthetics produce 
complex cardiovascular actions that may improve 
the myocardial oxygen supply and demand 
relationship, it is equally clear that such salutary 
alterations in the determinants of myocardial 
metabolism and coronary perfusion are not solely 
responsible for the anti-ischemic actions of these 
agents. For example, halothane confers 
protection during cardioplegic arrest [2] and upon 
reperfusion [30], circumstances in which 
myocardial metabolism plays little if any role. 
Isoflurane and sevoflurane also increase viability 
of isolated cardiac myocytes exposed to a cellular 
model of ischemia [31]. These results were 
initially attributed to reductions in excessive 
intracellular Ca2+ during ischemia and reperfusion 
[32] by partial inhibition of cl+ channel activity 
during administration of these drugs [33, 34, 35, 
36] . However, these data did not address specific 
mechanisms by which anesthetics produced 
protection nor did they provide insight into the 
intracellular processes responsible for these 
beneficial effects. 
MITOCHONDRIAL KATP CHANNELS: 
MEDIATORS OF IPC 
KATP channels are heteromultimeric 
+ 
complexes consisting of an inward-rectifying K 
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channel (Kir) and a sulfonylurea receptor (SUR) 
[37]. Pharmacological and recombinant 
techniques indicate that the cardiac sarcolemmal 
KATP channel [38] is composed of the 
Kir6.2/SUR2A isoforms. In contrast, the 
mitochondrial KATP channel [39] consists of the 
Kir6.1/SUR1 isoforms [40]. It was originally 
hypothesized that opening of sarcolemmal KATP 
channels protects ischemic myocardium by 
shortening the action potential duration and 
preventing intracellular Ca2+ overload [38]. 
However, other studies indicated that the 
beneficial actions of KATP channel activation 
occurred independent of the action potential 
duration [41, 42]. In fact, the vast majority of 
recent evidence suggests that mitochondrial KATP 
channels are the dominant mediators of IPC [43] 
and further, that preservation of mitochondrial 
bioenergetic function is vital for cytoprotection 
against myocardial ischemia [44, 45, 46, 47]. 
Mitochondrial K~TP channel openers maintain 
intracellular Ca + homeostasis and inhibit 
mitochondrial cl+ overload [46, 47]. These 
actions may enhance myocyte survival by 
preventing tissue necrosis or apoptosis [48]. 
Opening of mitochondrial KATP channels has been 
shown to inhibit apoptosis in rat ventricular 
myocytes [49] by attenuating oxidant stress upon 
reperfusion [50]. Alteration of the mitochondrial 
redox state by KATP channel opening may also 
promote cellular protection [47, 51). Experiments 
conducted in isolated cardiac mitochondria [47] 
indicate that membrane depolarization, matrix 
swelling, and the uncoupling of ATP synthesis that 
occurs as a result of increased oxygen 
consumption are effects associated with the 
opening of mitochondrial KATP channels that may 
mediate cellular viability during IPC [51). Opening 
of mitochondrial KATP channels depolarizes the 
inner mitochondrial membrane and causes a 
198 
transient swelling of the mitochondrial matrix [52], 
resulting from a shift in the ionic balance [53]. 
Mitochondrial KATP channel opening initially 
reduces ATP production as a result of membrane 
depolarization [47], but also subsequently 
stimulates a compensatory increase in respiration 
that optimizes oxidative phosphorylation efficiency 
in part through energy-dependent matrix volume 
regulation [54] . Thus, a moderate disturbance of 
mitochondrial homeostasis may promote 
myocardial tolerance to ischemic stress by altering 
. 2+ 
energetic systems to reduce Ca overload, 
prevent the activation of necrotic or apoptotic 
pathways, or attenuate oxidant stress. 
SIGNAL TRANSDUCTION IN APC 
KATP CHANNELS 
Experimental evidence accumulated in the 
Opioids 
Aden~ "-
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past seven years indicates that the endogenous 
mechanisms involved in APC bear striking 
similarity to those identified during IPC. It is 
hypothesized that a "trigger" initiates a cascade of 
signaling events leading to activation of an "end-
effector" that is responsible for resistance to injury. 
KATP channel activation has been implicated as 
the end-effector (figure 2) in this protective 
scheme during APC, as these channels have been 
shown to playa fundamental role in mediating 
myocardial protection during IPC [55, 56, 57]. A 
recent investigation using a cellular model of 
ischemia reported that administration of isoflurane 
and sevoflurane preserved myocyte viability 
compared to cells that were not exposed to a 
volatile agent. This protective effect was 
abolished by the selective mitochondrial KATP 
channel antagonist 5-hydroxydecanoic acid (5-HD) 
Figure 2. Schematic diagram illustrating volatile anesthetic-induced stimulation of 
endogenous signaling mechanisms responsible for myocardial protection. A "trigger" 
initiates a cascade of signal transduction events resulting in the activation of an 
"end-effector" that promotes resistance against cellular injury. Mitochondrial KATP 
channels have been implicated as the end-effector in this protective scheme, but 
sarcolemmal KATP channels may also playa role. Volatile anesthetics signal through 
adenosine and opioid receptors, modulate G proteins, or activate protein kinase C 
(PKC) and other intracellular kinases that subsequently open KATP channels. Volatile 
anesthetics also directly generate reactive oxygen species (ROS) in mitochondria 
that modulate KATP channel activity. 
Anesthetic-induced myocardial protection 
but not the selective sarcolemmal KATP channel 
antagonist HMR-1098 [31]. The nonselective 
KATP channel blocker glyburide completely 
attenuated the recovery of contractile function 
produced by isoflurane in stunned myocardium 
[13,58]. Isoflurane-induced reductions in canine 
myocardial infarct size [15] and the ATP-sparing 
effects of this agent [59] are also abolished by 
glyburide. 5-HD inhibits preconditioning by 
isoflurane in vivo in rats [16], rabbits [60], and 
isolated human atria [61, 62]. Both HMR-1098 
and 5-HD abolished the protective effects of 
desflurane in dogs [63], supporting a role for both 
sarcolemmal and mitochondrial KATP channels in 
APC. These latter data contrast to some degree 
with findings that implicate mitochondrial KATP 
channels alone as the predominant mediators of 
IPC[43]. 
Results from carefully conducted in vitro 
experiments using pharmacological techniques 
strongly suggested that volatile anesthetics 
directly activate KATP channels. Isoflurane 
stimulated outward K+ current through 
sarcolemmal KATP channels in isolated ventricular 
myocytes during patch-clamping [64, 65] . Volatile 
anesthetics also reduced sarcolemmal KATP 
channel sensitivity to inhibition by ATP, thereby 
increasing the open state probability [66] . In 
contrast, other studies indicate volatile anesthetics 
alone were unable to elicit cha'lnel opening, but 
these agents did enhance sarcolemmal KATP 
channel current by facilitating channel opening 
after initial activation [64, 65]. Isoflurane and 
sevoflurane increased mitochondrial flavoprotein 
oxidation, an index of mitochondrial KATP channel 
activity, in guinea pig cardiac myocytes, and this 
endogenous autofluorescence was inhibited by 5-
HD [67]. Isoflurane and sevoflurane also 
enhanced diazoxide-induced flavoprotein 
fluorescence in isolated rat ventricular myocytes 
[31]. Interestingly, isoflurane failed to augment 
KATP channel current in excised membrane 
patches [64]. These data suggest that volatile 
a'nesthetics may not directly interact with 
sarcolemmal KATP channels, but instead act upon 
other intracellular signaling elements that 
modulate KATP channel activity. In contrast to the 
findings with isoflurane, halothane had no effect 
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on pinacidil-induced increases in sarcolemmal 
KATP channel current. Halothane also inhibited 
KATP channel current that had been maximally 
activated by 2,4-dinitrophenol [65]. Thus, the 
preponderance of evidence collected to date 
suggest that volatile anesthetics may not directly 
open KATP channels, but instead prime the 
activation of these channels in both sarcolemmal 
and mitochondrial membranes. This hypothesis is 
partially supported by the observation during IPC 
that adenosine facilitates KATP channel activation 
during myocardial ischemia through a PKC-
dependent mechanism [68]. Taken as a whole , 
the experimental results with volatile anesthetics 
are consistent with previous findings 
demonstrating that pharmacological stimulation of 
KATP channels with other drugs mimics the 
conditions present during IPC [69]. 
Volatile anesthetics may activate parallel or 
redundant signal transduction pathways that 
involve KATP channel opening to generate a 
physiologically-meaningful cellular response. The 
sequential activation of several intracellular 
elements within a given transduction pathway may 
facilitate signal amplification and interaction 
between other redundant signaling systems. For 
example, administration of isoflurane in the 
presence of the KATP channel opener nicorandil 
[70] or diazoxide [71] markedly enhances 
protection against ischemic injury beyond that 
observed with either drug alone. Interestingly, the 
combination of isoflurane and a selective ~1-opioid 
receptor agonist amplifies the preconditioning 
response in the rat [71]. This effect is synergistic, 
and is sensitive to inhibition by glyburide [71]. 
Recent experiments also demonstrate that 
combined administration of isoflurane and 
morphine also markedly reduces infarct size in 
vivo. This enhanced protective effect is abolished 
by 5-HD [16]. These data suggest that combined 
administration of a volatile anesthetic and an 
opioid may stimulate similar or cooperative 
signaling cascades that amplify KATP channel 
activation to profoundly augment myocardial 
protection beyond that produced by either drug 
alone. 
KATP channels in vascular smooth muscle 
cells have been shown to be essential regulators 
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of coronary vascular tone when ATP production is 
reduced [72]. Volatile anesthetic-induced coronary 
vasodilation [11 , 19, 20,21 , 22,23] is attenuated 
by glyburide, indicating an important role for KATP 
channels in this process. Thus, it remains 
possible that the beneficial actions of APC may be 
partially attributed to increased oxygen supply 
mediated by KATP channel-dependent coronary 
vasodilation. However, sevoflurane increases 
coronary collateral blood flow in the presence of 
glyburide in vivo, indicating that volatile 
anesthetics enhance coronary collateral blood flow 
independent of KATP channel activation [23]. In 
fact, we have recently shown that sevoflurane-
induced increases in collateral perfusion occurs as 
2+ . 
a result of Ca -regulated potassium (BKca) and 
not KATP channel activation [73]. In addition, 
isoflurane and sevoflurane directly activate 
mitochondrial KATP channels in isolated cardiac 
myocytes, and this action is linked to enhanced 
cell viability [31] . Based on these data, it appears 
highly unlikely that myocardial protection produced 
by volatile anesthetics is solely related to favorable 
alterations in coronary vascular tone mediated by 
KATP channels. 
ADENOSINE AND OTHER G-PROTEIN 
COUPLED RECEPTORS 
Several receptor-mediated events and 
intracellular signaling elements that converge on 
the KATP channel have been implicated in APC. 
Pertussis toxin abolished reductions in infarct size 
produced by isoflurane, indicating that inhibitory 
guanine (G;) nucleotide-binding proteins are linked 
to the signal transduction pathways that mediate 
APC [74] . In contrast, pertussis toxin did not 
prevent the beneficial effects of direct KATP 
channel opening produced by nicorandil. These 
data strongly supported the contention that volatile 
anesthetics modulate KATP channel activity 
through a second messenger. Halothane-induced 
protection against infarction was completely 
abolished by blockade of the adenosine type 1 
(A1) receptor [6], and a selective A1 receptor 
antagonist also partially attenuated the beneficial 
effects of isoflurane in stunned myocardium [75]. 
Isoflurane eliminated increases in interstitial 
adenosine during repetitive periods of coronary 
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artery occlusion and reperfusion as demonstrated 
using a myocardial microdialysis technique [75]. 
These novel findings suggest that ATP 
preservation and a subsequent reduction of 
adenosine released into the interstitium occur 
during isoflurane anesthesia. The results are also 
very similar to findings during IPC [76] and 
pharmacological preconditioning produced by 
bimakalim [77]. The results further indicate that 
volatile anesthetics may either directly activate A1 
receptors or indirectly enhance A1 receptor 
sensitivity to diminished endogenous adenosine 
concentrations [75] . The preservation of cardiac 
myocyte viability during ischemia produced by 
volatile anesthetics is also sensitive to adenosine 
receptor and G; protein-mediated signaling 
blockade [31]. Additional findings indicate that the 
nonselective opioid antagonist naloxone abolishes 
isoflurane-induced preconditioning in the rat [16]. 
These intriguing data suggest an important link 
between volatile anesthetics and another family of 
G protein-coupled receptors. In fact, new 
evidence reveals that volatile agents competitively 
inhibit the ligand-binding site of G protein-coupled 
receptors [78]. Thus, APC appears to be 
associated with the activation of at least two 
separate receptor-mediated pathways (A1 and 8-
opioid) that are linked to G; proteins. 
PROTEIN KlNASE C 
APC may also produce translocation and 
phosphorylation of several protein kinases 
involved in signal transduction [79,80,81]. PKC 
is an essential component of the signaling 
pathway involved in protecting the myocardium 
against cell death after ischemia and reperfusion 
[82]. The diverse PKC isoform family is a large 
group of serine/threonine protein kinases that are 
distinguished by variable regulatory domains and 
cofactors, and also display diverse tissue and 
species distributions [83]. Volatile anesthetics 
stimulate PKC translocation and activity [84], 
possibly by interacting with the regulatory domain 
of the enzyme[85]. Inhibition of PKC attenuates 
isoflurane-induced augmentation of the functional 
recovery of stunned myocardium in dogs [86]. 
The beneficial actions of halothane are entirely 
blocked by selective PKC antagonism in rabbits 
[6]. The microtubule depolymerizing drug, 
colchicine, prevents isoflurane-induced reductions 
Anesthetic-induced myocardial protection 
in myocardial infarct size in rabbits [87]. This 
interesting result suggests that an intact 
cytoskeleton may be essential for translocation of 
these protein kinases to occur. 
Recent findings strongly suggest that 
volatile anesthetic-induced PKC translocation and 
activation is required to open KATP channels and 
produce myocardial protection. For example, the 
nonselective PKC antagonist chelerythrine 
abolished sevoflurane-induced increases in 
mitochondrial KATP channel activity in rat 
ventricular myocytes [31] and prevents protection 
from ischemic damage. Patch-clamp 
experiments demonstrate that isoflurane does not 
facilitate KATP channel opening in excised 
membrane patches, but enhances KATP channel 
current in a whole-cell configuration concomitant 
with PKC stimulation [64]. These observations are 
supported by additional evidence illustrating that 
both adenosine and PKC enhance KATP channel 
activity [71, 88, 89, 90, 91]. In fact, specific PKC 
consensus sites are located on KATP channels, 
indicating a molecular basis for phosphorylation 
and activation of the channel by the enzyme [92]. 
Mitochondrial KATP channel opening occurs after 
PKC activation during IPC in isolated rabbit hearts 
[93]. Other intracellular kinases may also be 
involved in the signaling pathways mediating the 
cellular response to ischemia because PKC 
stimulates tyrosine [94] and mitogen-activated 
protein (MAP) kinases [95] as well. Thus, volatile 
anesthetics also appear to modulate several 
critical intracellular signaling proteins independent 
of direct receptor activation (figure 2). 
REACTIVE OXYGEN SPECIES 
Reperfusion of ischemic myocardium is 
associated with the release of large quantities of 
reactive oxygen species (ROS) [96, 97, 98] that 
disrupt intracellular homeostasis, depress 
contractility, and produce tissue injury. Halothane, 
isoflurane, and enflurane has been shown to 
attenuate the toxic effects of oxygen-derived free 
rc;ldicals on left ventricular pressure development 
in isolated hearts [99]. Isoflurane decreases 
hydroxyl radical generation in the ischemic rat 
heart [100] and halothane has a similar effect in 
dogs [101]. The protective effects of sevoflurane 
are associated with reduced dityrosine formation, 
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an indirect marker of reactive oxygen and nitrogen 
species [102]. These results support the 
contention that volatile anesthetics may reduce the 
release of deleterious quantities of reactive 
oxygen species immediately after coronary artery 
occlusion. 
In contrast to these data implicating a 
pathological role of large amounts of ROS, new 
evidence strongly suggests that a variety of 
preconditioning stimuli, including brief ischemia, 
mitochondrial KATP channel openers, opioids, and 
volatile anesthetics, stimUlate a small burst of 
ROS that paradoxically appears to initiate 
downstream signaling events and produce 
protection from subsequent ischemic injury. The 
beneficial actions of sevoflurane against ischemic 
damage are abolished by scavengers of 
superoxide and inhibition of nitric oxide synthase 
[102]. These results suggest that superoxide may 
act to trigger APC and also indicate that nitric 
oxide may scavenge superoxide upon reperfusion 
to reduce injury. ROS scavengers attenuate 
isoflurane-induced reductions in myocardial infarct 
size in rabbits [103, 104] as shown in figure 3, and 
also inhibit the salutary effects of IPC [105, 106] or 
mitochondrial KATP channel activation [107]. We 
have recently demonstrated that isoflurane directly 
increases superoxide formation in vivo (figure 4) 
independent of ischemia and reperfusion [104]. 
These data [104] indicate that volatile anesthetics 
are capable of producing small amounts of ROS 
that may exert protective effects during 
subsequent ischemia. Notably, pretreatment with 
low concentrations of ROS mimic the beneficial 
actions of IPC and reduce infarct size through a 
PKC-mediated mechanism [108]. These reports 
provide compelling evidence that small quantities 
of ROS playa critical role in APC. 
Activation of mitochondrial KATP channels 
is associated with the ROS generation [109]. 
Mitochondrial KATP channel opening produced by 
selective agonists generates ROS that appear to 
be essential for activation of MAP kinase [110] and 
beneficial effects on myocardium [111]. Morphine 
increases cardiac myocyte viability and the 
fluorescence intensity of the hydrogen peroxide-
sensitive probe, 2'7'-dichlorofluorescin. These 
actions are blocked by 5-HD [112], suggesting that 
activation of mitochondrial KATP channels by 
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Figure 3. Histogram depicting myocardial infarct size expressed as the percentage 
of the left ventricular area at risk (AAR) in rabbits exposed to isoflurane in the 
presence and absence of the reactive oxygen species (ROS) scavengers N-
acetylcysteine (NAC) and 2-mercaptopropionylglycine (2-MPG). NAC and 2-MPG 
attenuated isoflurane-induced myocardial protection (ISO + NAC and ISO + 2-MPG. 
respectively). Other groups: control (CON). isoflurane alone (ISO). NAC alone 
(NAC). 2-MPG alone (2-MPG). (Adapted with permission of authors and publisher 
[104].) 
Control Isoflurane 
Figure 4. Photomicrographs demonstrating superoxide anion production using 
dihydroethidium fluorescence in rabbits. Isoflurane significantly (P < 0.05) increased 
fluorescence intensity of stained myocardial nuclei compared to control. (Adapted with 
permission of authors and publisher [104].) 
Anesthetic-induced myocardial protection 
opioids results in the RaS production. 
Mitochondria have been hypothesized to be a 
source of RaS production [106, 113, 114, 115, 
116], but whether opening of mitochondrialKATP 
channels directly contribute to free radical 
generation remains unknown. Conversely, RaS 
may also modulate KATP channel activity [117] to 
provide a beneficial effect. 
The identities of the RaS involved in APC 
and IPC and the signaling cascades that are 
modulated by these free radicals also remain 
unclear. RaS have been shown to activate PKC, 
restore contractility, and limit the extent of 
myocardial infarction [108]. Hydrogen peroxide 
stimulates tyrosine kinase-dependent activation of 
phospholipase C (PLC) in mouse embryonic 
fibroblasts, rendering these cells resistant to stress 
[118] . RaS may also directly stimulate PKC 
activity [119] or indirectly enhance the activity of 
the enzyme by activation of PLC [118]. 
Interestingly, hydrogen peroxide activates G; and 
Go proteins [120, 121], as well as other protein 
kinases involved in reducing cellular injury [110, 
122, 123, 124]. Recent evidence suggests that 
hydrogen peroxide may be converted to more 
reactive species that modify cysteine residues 
specific to Gu; and Gao, resulting in selective 
activation of these proteins [120). Therefore, 
volatile anesthetic-induced production of Ras may 
directly activate intracellular mediators of 
endogenous protection against ischemic injury 
(figure 2). This tantalizing hypothesis will require 
further research to confirm. 
MYOCARDIAL PROTECTION BY VOLATILE 
ANESTHETICS IN HUMANS 
Evidence accumulated to date strongly 
suggests that APC occurs in human myocardium, 
but evaluation of this process in patients is 
complicated by alterations in systemic and 
coronary hemodynamics, the use of other 
anesthetics, analgesics, or vasoactive drugs, 
preexisting disease states, and the influence of 
surgery on cardiovascular homeostasis. 
Isoflurane [62] and desflurane [125] enhance the 
recovery of contractile function of human atrial 
trabeculae by stimulation of adenosine receptors 
and opening of KATP channels [62]. Other studies 
have previously demonstrated a role for adenosine 
receptors, MAP kinases [61], and ROS [126] in 
other forms of preconditioning in human atrial 
myocytes concomitant with opening of 
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mitochondrial KATP channels. Isoflurane 
increases the tolerance to pacing-induced 
ischemia in patients with coronary artery disease 
[127]. Isoflurane also decreases postoperative 
release of troponin I and creatine kinase-MB in 
patients undergoing coronary artery bypass graft 
(CABG) surgery, suggesting a reduction in the 
severity of myocardial necrosis [128]. 
Administration of enflurane before cardioplegic 
arrest also enhances postischemic contraotile 
functional recovery in CABG patients [129]. Most 
recently, sevoflurane but not the intravenous 
anesthetic propofol was shown to preserve 
myocardial function in patients undergoing CABG 
concomitant with a reduction in troponin I release 
[130]. This compelling evidence emphasizes that 
volatile anesthetics exert beneficial effects against 
ischemic injury in humans and dispels the 
previously held contention that these agents may 
produced adverse redistribution of coronary 
collateral blood flow away from ischemic 
myocardium ("coronary steal") in certain patients 
with coronary artery disease. It has become 
increasingly clear that preexisting ischemia on 
arrival to the operating room and not anesthetic 
technique is the strongest predictor of 
intraoperative ischemia [131,132]. However, 
volatile anesthetics may represent an important 
therapeutic modality to reduce the risk of 
perioperative myocardial ischemia and infarction 
[133] , although this conclusion has yet to be 
confirmed in a large-scale, randomized, clinical 
trial. 
SUMMARY 
Experimental and clinical evidence 
indicates that volatile anesthetics exhibit important 
anti-ischemic actions that reduce the sequelae of 
reversible and irreversible ischemic injury. 
Several endogenous signaling elements mediate 
APC, but the mitochondrial KATP channel appears 
to be a central feature involved in maintaining 
function and promoting myocyte survival. 
Preservation of mitochondrial integrity and 
metabolic homeostasis by volatile anesthetics may 
ultimately enhance tolerance to myocardial 
ischemia. Translation of strong experimental data 
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about the protective effects of volatile anesthetics Anesthesiology, (In Press). 
and other protective drugs, including opioids, into 17. Cason, B. A, Gamperl, A K., Slocum, R. 
therapeutic approaches to reduce morbidity and E., and Hickey, R. F. 1997, Anesthesiology, 
mortality in patients with coronary artery disease 87, 1182. 
remains to be established. 18. Toller, W G., Kersten, J. R., Pagel, P. S., 
Hettrick, D. A , and Warltier, D. C. 1999, 
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